BRPI0911772A2 - composto, composição farmacêutica, e, uso do composto. - Google Patents

composto, composição farmacêutica, e, uso do composto.

Info

Publication number
BRPI0911772A2
BRPI0911772A2 BRPI0911772A BRPI0911772A BRPI0911772A2 BR PI0911772 A2 BRPI0911772 A2 BR PI0911772A2 BR PI0911772 A BRPI0911772 A BR PI0911772A BR PI0911772 A BRPI0911772 A BR PI0911772A BR PI0911772 A2 BRPI0911772 A2 BR PI0911772A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0911772A
Other languages
English (en)
Portuguese (pt)
Inventor
Sonesson Clas
Karlsson Jonas
Svensson Peder
Original Assignee
Nsab Filial Af Neurosearch Sweden Ab Sverige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Filial Af Neurosearch Sweden Ab Sverige filed Critical Nsab Filial Af Neurosearch Sweden Ab Sverige
Publication of BRPI0911772A2 publication Critical patent/BRPI0911772A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0911772A 2008-04-29 2009-04-28 composto, composição farmacêutica, e, uso do composto. BRPI0911772A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200800598 2008-04-29
PCT/EP2009/055137 WO2009133107A1 (en) 2008-04-29 2009-04-28 Modulators of dopamine neurotransmission

Publications (1)

Publication Number Publication Date
BRPI0911772A2 true BRPI0911772A2 (pt) 2017-06-27

Family

ID=40940061

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911772A BRPI0911772A2 (pt) 2008-04-29 2009-04-28 composto, composição farmacêutica, e, uso do composto.

Country Status (15)

Country Link
US (1) US8524766B2 (https=)
EP (1) EP2271634B1 (https=)
JP (1) JP5514804B2 (https=)
KR (1) KR20100135325A (https=)
CN (1) CN102036976B (https=)
AU (1) AU2009242092A1 (https=)
BR (1) BRPI0911772A2 (https=)
CA (1) CA2722978A1 (https=)
DK (1) DK2271634T3 (https=)
IL (1) IL208289A0 (https=)
MX (1) MX2010011724A (https=)
NZ (1) NZ588209A (https=)
RU (1) RU2010141964A (https=)
WO (1) WO2009133107A1 (https=)
ZA (1) ZA201006932B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133109A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2271638B1 (en) 2008-04-29 2011-08-31 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
CN102180856B (zh) * 2011-03-01 2016-01-20 浙江华海药业股份有限公司 一种制备6-氟-3,4-二氢-2h-1-苯并吡喃-2-甲酸乙酯的方法
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
DE112015002978T5 (de) 2014-06-26 2017-03-09 Sumitomo Chemical Company, Limited Verfahren zur Herstellung einer Phenolverbindung
US9125866B1 (en) 2015-01-28 2015-09-08 King Saud University Antidepressant compounds
WO2017014214A1 (ja) * 2015-07-21 2017-01-26 住友化学株式会社 4-(トリフルオロメチルスルホニル)フェノール化合物の製造方法
FI3976581T3 (fi) 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat
WO2024182774A1 (en) * 2023-03-01 2024-09-06 Alexander Shulgin Research Institute, Inc. Deuterated and fluorinated empathogens

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058980A (en) * 1962-10-16 Substitution products of benzo-
US2906757A (en) * 1959-09-29 Their preparation
DE1110175B (de) * 1957-01-08 1961-07-06 Rhone Poulenc Sa Verfahren zur Herstellung von Benzodioxanderivaten
JPS55124781A (en) * 1979-03-20 1980-09-26 Shionogi & Co Ltd 1,4-benzdioxanesulfonamide derivative
US5236055A (en) * 1991-03-13 1993-08-17 Canadian Aging & Rehabilitation Product Development Corporation Wheel with coaxial drive system mounted in the wheelhub field of the invention
US5126366A (en) * 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5189171A (en) * 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5166367A (en) * 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5684039A (en) * 1995-07-25 1997-11-04 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
AR004229A1 (es) 1995-11-06 1998-11-04 Wyeth Corp Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
JP2005505586A (ja) * 2001-10-04 2005-02-24 ワイス 5−ヒドロキシトリプタミン−6リガンドとしてのクロマン誘導体
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1678121A4 (en) * 2003-10-24 2007-07-25 Exelixis Inc MODULATORS OF TAO KINASES AND METHODS OF USE
KR100823805B1 (ko) * 2004-05-05 2008-04-21 에프. 호프만-라 로슈 아게 5-ht6 수용체, 5-ht2a 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산
DE602005021641D1 (de) * 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
AU2006239930A1 (en) 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
EP2271638B1 (en) 2008-04-29 2011-08-31 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
WO2009133109A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission

Also Published As

Publication number Publication date
US8524766B2 (en) 2013-09-03
AU2009242092A1 (en) 2009-11-05
EP2271634B1 (en) 2014-02-12
KR20100135325A (ko) 2010-12-24
IL208289A0 (en) 2010-12-30
US20110105461A1 (en) 2011-05-05
DK2271634T3 (da) 2014-05-05
MX2010011724A (es) 2010-11-30
CN102036976B (zh) 2013-05-01
JP5514804B2 (ja) 2014-06-04
RU2010141964A (ru) 2012-06-10
CN102036976A (zh) 2011-04-27
ZA201006932B (en) 2011-12-28
NZ588209A (en) 2012-08-31
EP2271634A1 (en) 2011-01-12
WO2009133107A1 (en) 2009-11-05
JP2011518858A (ja) 2011-06-30
CA2722978A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]